KBC Group NV Raises Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

KBC Group NV lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 65.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 424,739 shares of the medical equipment provider’s stock after purchasing an additional 168,210 shares during the period. Intuitive Surgical accounts for approximately 0.6% of KBC Group NV’s holdings, making the stock its 21st largest position. KBC Group NV owned about 0.12% of Intuitive Surgical worth $208,661,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Creekmur Asset Management LLC raised its stake in Intuitive Surgical by 200.0% during the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares during the period. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical in the 2nd quarter worth $26,000. Delos Wealth Advisors LLC raised its position in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 57 shares in the last quarter. Godsey & Gibb Inc. boosted its position in shares of Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares during the period. Finally, LRI Investments LLC purchased a new stake in shares of Intuitive Surgical in the first quarter worth approximately $30,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Trading Down 0.1 %

Shares of ISRG opened at $536.69 on Thursday. The company’s 50-day moving average price is $495.85 and its 200 day moving average price is $455.08. Intuitive Surgical, Inc. has a 12-month low of $287.98 and a 12-month high of $542.59. The firm has a market cap of $191.16 billion, a P/E ratio of 86.28, a price-to-earnings-growth ratio of 5.28 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.32. The company had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. Equities research analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In related news, insider Jamie Samath sold 269 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $539.89, for a total transaction of $145,230.41. Following the sale, the insider now directly owns 8,757 shares in the company, valued at approximately $4,727,816.73. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Gary S. Guthart sold 18,151 shares of the stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total value of $9,286,596.13. Following the transaction, the chief executive officer now owns 24,219 shares in the company, valued at approximately $12,391,166.97. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jamie Samath sold 269 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $539.89, for a total value of $145,230.41. Following the sale, the insider now directly owns 8,757 shares in the company, valued at $4,727,816.73. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 91,178 shares of company stock worth $45,897,071. Company insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

ISRG has been the topic of a number of research analyst reports. Piper Sandler restated an “overweight” rating and issued a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Citigroup increased their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Mizuho raised their price target on Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their price objective on Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $513.74.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.